Wholesale Acquisition Cost (WAC

)
Pricing of Select Regimens1-9
Total duration of therapy (weeks)a 12 12 24 24 48 24 48 28 36 48 24 24 48 Total regimen cost b $94,078 $84,823 $169,646 $86,312 $106,468 $86,516 $106,673 $64,825 $85,257 $95,845 $19,608 $21,176 $42,352 Incremental Treatment Cost at Select Time Points Week 12 $94,078 $84,823 $84,823 $76,233 $76,233 $76,438 $76,438 $23,961 $23,961 $23,961 $9,804 $10,588 $10,588 $28,274 $3,359 $3,359 $3,359 $3,359 $10,216 $10,216 $10,216 $3,268 $3,529 $3,529 $28,274 $3,360 $3,359 $3,359 $3,359 $10,216 $10,216 $10,216 $3,268 $3,529 $3,529 $28,275 $3,360 $3,359 $3,360 $3,359 $10,216 $10,216 $10,216 $3,268 $3,530 $3,529 $3,529 $3,360 $10,216 $10,216 $10,216 $3,360 Week 16 Week 20 Week 24 Week 28 Week 36 Week 48

Regimen SOVALDI® + PEGASYS® + ribavirin  SOVALDI® + ribavirin  SOVALDI® + ribavirin  INCIVEK® + PEGASYS® + ribavirin INCIVEK® + PEGASYS® + ribavirin OLYSIO™ + PEGASYS® + ribavirin OLYSIO™ + PEGASYS® + ribavirin VICTRELIS® + PEGINTRON® + ribavirin VICTRELIS® + PEGINTRON® + ribavirin VICTRELIS® + PEGINTRON® + ribavirin PEGASYS® + ribavirin  PEGINTRON® + ribavirin  PEGINTRON® + ribavirin 

// $6,718 // $10,080 // $6,718 // $10,080 // $20,432 // $20,432 // $10,588

// $7,058 // $10,590

a. Based on approved dosing for complete course of therapy. Follows full prescribing information recommendations for each product. b.  Total regimen costs assume average weight of typical patient (86.2 kg) calculated using anthropometric reference data for US adults compiled by the US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) in 2007-2010 and CDC data showing 87% of US individuals were born between 1945 and 1970 and two-thirds of this cohort are male.10,11 Ribavirin costs were based on the average generic price for capsules and tablets. Assumes no dose reduction due to adverse events and that patient takes entire regimen as indicated. Not all components may be used for the full duration. Cost for PEGASYS® based on the cost of PROCLICK™ autoinjectors and prefilled syringes, which are priced the same. Cost for PEGINTRON® based on the cost of REDIPEN®s and single-dose kits (powder + dilutent vials), which are priced the same.

For reference only. Cost comparisons of agents do not imply comparable clinical effectiveness, safety, tolerability, or that these products have the same or similar indications or uses. Please refer to the full prescribing information for each product. Individual prescribing decisions should be made at the discretion of the provider. • The  information reflects WAC prices as reported by First Databank™ (FDB) on February 27, 2014. Manufacturers change the WAC prices of their products periodically. Current WAC prices may be obtained by contacting FDB. • WAC  = wholesaler acquisition cost, or manufacturer’s published price to wholesalers; WAC represents published catalogue or list prices and may not represent actual transactional prices. • For  further information concerning pricing methodology, please refer to this section of the FDB website (http://www.fdbhealth.com/policies/drug-pricing-policy/). •  Pricing information reprinted with permission by First Databank, Inc. All rights reserved. ©2014

References: 1. SOVALDI® [package insert]. Foster City, CA: Gilead Sciences, Inc; December 2013. 2. FDB Medknowledge™. South San Francisco, CA: First Databank™; 2014. 3. Pegasys [package insert]. South San Francisco, CA: Genentech Inc; 2013. 4. Pegintron [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013. 5. Rebetol [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013. 6. Copegus [package insert]. South San Francisco, CA: Genentech Inc; 2013. 7. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; 2013. 8. Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2013. 9. Olysio [package insert]. Titusville, NJ; Janssen Therapeutics, Division of Janssen Products, LP; 2013. 10. Smith BD, Morgan RL, Beckett GA, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32. 11. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Anthropometric reference data for children and adults: United States, 2007–2010. Data from the National Health and Nutrition Examination Survey. Vital Health Stat Ser 11. 2012;(11)252:1-40. HHS publication no. (PHS) 2013-1602.

GILEAD, the GILEAD Logo, SOVALDI, and the SOVALDI Logo are trademarks of Gilead Sciences, Inc., or its related companies. All other marks are the property of their respective owners. ©2014 Gilead Sciences, Inc. All rights reserved. SVDP0010 02/14